Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Nonpeptide small molecule
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 896
Molecular formula: C13H16N2O2
IUPAC: N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
Source: PC-MELATONIN
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Nonpeptide indole hormone signaling through MT1/MT2 receptors and participating in circadian timing.
Evidence and critical reading
Reported scientific and empirical uses
Sleep and circadian rhythms
Sleep/circadian contexts; timing, formulation and population matter alongside amount.
Human evidence
In the EU, prolonged-release Circadin has a specific primary-insomnia indication in people aged 55 and over. This does not establish efficacy for all forms, ages or longevity uses.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
In the EU, prolonged-release Circadin has a specific primary-insomnia indication in people aged 55 and over. This does not establish efficacy for all forms, ages or longevity uses.
In the EU, prolonged-release Circadin has a specific primary-insomnia indication in people aged 55 and over. This does not establish efficacy for all forms, ages or longevity uses.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by EMA: Circadin, melatonin prolonged-release
2 mg · Amount per administration
- Frequency
- Once/day
- Duration
- Up to 13 weeks per labeling
- Route
- Oral, prolonged release
- Context
- Circadin, EU, primary insomnia age ≥55; not every melatonin formulation.
- Presentation
- 2-mg prolonged-release tablet.
- Interpretation
- Product/indication specification; not a personal recommendation.
EMA-CIRCADIN · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
EU: prolonged-release Circadin melatonin is authorized for short-term primary insomnia in patients ≥55 years. Other formulations/jurisdictions need separate review.
Adverse effects and unknowns
Somnolence and driving ability matter; fluvoxamine increases exposure and other sedatives can potentiate impairment per labeling.
Contraindications
Circadin: hypersensitivity to active substance/excipients; lack-of-data nonrecommendations are distinct from formal contraindications.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Fluvoxamine increases melatonin exposure; sedatives may increase functional impairment. Interactions concern the labeled product.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Melatonin · 722 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT00097474 · Effects of Hydrocortisone, Melatonin, and Placebo on Jet LagRegistry status: CompletedLast update posted: October 16, 2026Query verification: October 16, 2026
NCT00262470 · Treatment of Orthostatic IntoleranceRegistry status: Active, not recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07869030 · Melatonin Effect on Immediate Dental Implants in the Posterior MandibleRegistry status: RecruitingLast update posted: October 15, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- EMA-CIRCADIN
EMA: Circadin, melatonin prolonged-release
October 16, 2026
- PC-MELATONIN
October 16, 2026
- SEARCH-PUBMED-melatonin
PubMed/MED targeted search: TITLE_ABS:melatonin AND TITLE_ABS:randomized AND TITLE_ABS:insomnia
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026